Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease
Authors not listed
Shanghai Greenvalley Pharmaceutical Co., Ltd. · 2011
Abstract
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2011). Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease. <em>Shanghai Greenvalley Pharmaceutical Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT01453569
Vancouver
Anonymous. Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease. Shanghai Greenvalley Pharmaceutical Co., Ltd.. 2011.
BibTeX
@misc{anon2011PhaseI,
title = {Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease},
author = {Anonymous},
journal = {Shanghai Greenvalley Pharmaceutical Co., Ltd.},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Shanghai Greenvalley Pharmaceutical Co., Ltd. 2014
Open access · US-GOV
Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease
Memory Pharmaceuticals 2005
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease
Memory Pharmaceuticals 2007
Open access · US-GOV
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease
University Hospitals Cleveland Medical Center 2012
Open access · US-GOV
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Medivation, Inc. 2009
Open access · US-GOV
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease
Pfizer 2009
Open access · US-GOV